Clinical Trial

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Study acronym: SCALA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-04
Trial Details
NCT Number NCT07725939
Lead Sponsor UCB Biopharma SRL
Conditions Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Enrollment 402 participants
Start Date 2026-07-27
Primary Completion 2029-06-29 (estimated)
Study Completion 2029-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-03